<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345631</url>
  </required_header>
  <id_info>
    <org_study_id>EM0501</org_study_id>
    <nct_id>NCT00345631</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device</brief_title>
  <official_title>ECLIPSE Trial - Ensure's Vascular Closure Device Speeds Hemostasis Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the Ensure Medical Vascular Closure Device
      is more effective than standard manual compression at sealing the puncture made in the
      femoral artery following a cardiac or peripheral diagnostic or interventional procedure while
      maintaining the same level of safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Achieving hemostasis at the arterial puncture site after percutaneous cardiac catheterization
      is a potential cause of bleeding, hematomas, pseudoaneurysms, and various other vascular
      complications. Hemostasis at the femoral artery access site after diagnostic or
      interventional procedures is typically achieved using either manual compression or the
      deployment of a vascular closure device. Manual compression is time consuming for the
      health-care provider, and painful for the patient. In addition, prolonged periods of
      immobilization and bed rest may be required. Vascular closure devices have been developed to
      avoid manual compression, shorten bed rest, and allow earlier ambulation.

      The Ensure Medical Vascular Closure device (VCD) is intended for femoral artery puncture site
      closure in patients who have undergone coronary or peripheral diagnostic or interventional
      procedure using a standard 6F introducer sheath. The device is comprised of a bio-absorbable
      plug and a plug delivery system. The plug delivery system is designed to position the
      bio-absorbable plug to the extravascular surface of the femoral artery access site,
      facilitating a hemostasis response. The Ensure Medical VCD has been studied in a prior
      feasibility trial of 149 patients, which demonstrated that: (1) the device could be used to
      successfully obtain rapid hemostasis and early ambulation in patients undergoing
      catheterization procedures; and (2) the low incidence and relatively minor nature of the
      observed closure related complications suggests that the device is safe for its intended
      purpose.

      The ECLIPSE Trial is designed to evaluate the safety and effectiveness of the Ensure Medical
      VCD in comparison to standard manual compression. Patients will be randomly assigned to have
      their arterial access site closed using either manual compression or the VCD. The principal
      comparisons of the two closure techniques will include:

        -  Time required to obtain hemostasis of the vascular access site

        -  Time required for the patient to ambulate after their catheterization

        -  Frequency of occurrence of serious closure-related complications
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Hemostasis (TTH)</measure>
    <time_frame>From when the introducer sheath was removed to the time hemostasis was first observed</time_frame>
    <description>Time to hemostasis is defined as time (in minutes) from when the introducer sheath was removed to the time that hemostasis was first observed during post-procedure follow up. Hemostasis is defined as no or minimal subcutaneous oozing and the absence of expanding or developing hematoma. Time to hemostasis is one of the two co-primary endpoints.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Ambulation (TTA)</measure>
    <time_frame>From when the introducer sheath was removed to 30 days post-procedure</time_frame>
    <description>Time to ambulation is defined as the time from when the introducer sheath was removed to the time that ambulation was achieved. Ambulation is defined as patient standing and walking at least 20 feet without re-bleeding or significant oozing requiring manual compression. Time to ambulation is one of the two co-primary endpoints.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients Who Experience Any Vascular Closure Related Major Adverse Events During the 30 Days Post-procedure</measure>
    <time_frame>From post-procedure to 30 days follow up</time_frame>
    <description>Vascular closure related major adverse events consist of any of the events below: Vascular repair or the need for repair; access site-related bleeding requiring transfusion; access site-related infection requiring intravenous/intramuscular antibiotics and/or extended hospitalization; any new ipsilateral lower extremity ischemia documented by symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram; surgery for access site-related nerve injury; and Permanent (&gt; 30 days) access site-related nerve injury.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Eligibility for Hospital Discharge</measure>
    <time_frame>From introducer sheath removal to hospital discharge, up to 284 hours</time_frame>
    <description>Time to Eligibility for Hospital Discharge is measured from the time of sheath removal to the time when the patient is eligible for discharge according to the judgment of the patient's physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospital Discharge</measure>
    <time_frame>From introducer sheath removal to patient discharge</time_frame>
    <description>Time to hospital discharge is defined as from the time of sheath removal to the time of hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Device Deployment, up to 5 Minutes</measure>
    <time_frame>From device inserted to introducer sheath removal</time_frame>
    <description>Time to device deployment is defined as from the time device inserted to the time sheath removed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Achieved Device Success Within Five Minutes Post-procedure</measure>
    <time_frame>Within 5 minutes post-procedure</time_frame>
    <description>Device Success is defined as the successful deployment of the plug, initial hemostasis time less or equal to 5 minutes, and removal of the intact delivery system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Who Achieved Procedure Success During 30 Days Post-procedure</measure>
    <time_frame>From catheterization procedure to 30 day post-procedure follow up</time_frame>
    <description>Procedure success is defined as initial hemostasis achieved by the assigned method Vascular Closure Device (VCD) or Manual compression (MC) with none of the primary safety endpoint's closure related major adverse events (MAE). Procedural success is assessed on day of catheterization procedure and at 30 days post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Experienced Any Other Vascular Closure Related Adverse Events</measure>
    <time_frame>From end of vessel closure procedure to 30 days post-procedure</time_frame>
    <description>Other known vascular closure related adverse events include: Rebleeding Following Initial Hemostasis; Access Site Hematoma &gt;= 6cm; Access Site-Related Bleeding Requiring &gt; 30 min for Hemostasis; Transient Access Site-Related Nerve Injury; Retroperitonea Bleeding; Decrease in Pedal Pulse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">488</enrollment>
  <condition>Angioplasty, Transluminal, Percutaneous Coronary</condition>
  <condition>Coronary Arteriosclerosis</condition>
  <condition>Peripheral Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>Manual Compression</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Manual compression (MC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vascular Closure Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vascular Closure Device (VCD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Manual Compression</intervention_name>
    <description>Manual compression</description>
    <arm_group_label>Manual Compression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vascular Closure Device</intervention_name>
    <description>Investigational vascular closure device</description>
    <arm_group_label>Vascular Closure Device</arm_group_label>
    <other_name>Exoseal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for a coronary or peripheral diagnostic or interventional procedure

          -  Able to undergo emergent vascular surgery if a complication requires it

          -  6F arterial puncture located in the common femoral artery

          -  Femoral artery has a lumen diameter of at least 5 mm

        Exclusion Criteria:

          -  Arterial puncture in the femoral artery of both legs

          -  Prior target artery closure with any vascular closure device, or closure with manual
             compression within 30 days prior to catheterization

          -  Patients who bruise or bleed easily or with a history of significant bleeding or
             platelet disorders

          -  Acute ST-elevation myocardial infarction within 48 hours prior to catheterization

          -  Uncontrolled hypertension at time of vessel closure

          -  Elevated Activated Clotting Time at time of vessel closure

          -  Ineligible for in-catheterization lab introducer sheath removal

          -  Concurrent participation in another investigational device or drug trial

          -  Thrombolytic therapy, bivalirudin, other thrombin-specific anticoagulants, or low
             molecular weight heparin within 24 hours prior to catheterization

          -  Preexisting hematoma, arteriovenous fistula, or pseudoaneurysm at the vessel access
             site prior to femoral artery closure

          -  Prior femoral vascular surgery or vascular graft in region of access site

          -  Femoral artery is tortuous or requires an introducer sheath longer than 11 cm

          -  Fluoroscopically visible calcium, atherosclerotic disease, or stent within 1 cm of the
             puncture site that would interfere with the operation of the experimental device

          -  Difficulty in obtaining vascular access resulting in multiple arterial punctures
             and/or posterior arterial puncture

          -  Antegrade vascular puncture

          -  Body Mass Index over 40 kg/m^2

          -  Symptomatic leg ischemia in the target limb including severe claudication or
             weak/absent pulse

          -  Femoral artery diameter stenosis exceeding 50%

          -  Pre-existing severe non-cardiac systemic disease or terminal illness

          -  Planned arterial access at the same access site within 30 days of catheterization

          -  Extended hospitalization (e.g. Coronary Artery Bypass Graft (CABG) surgery)

          -  Pre-existing systemic or cutaneous infection

          -  Prior use of an intra-aortic balloon pump through the arterial access site

          -  Cardiogenic shock during or immediately following the catheterization

          -  Patient is unable to ambulate at baseline

          -  Patient is known or suspected to be pregnant or is lactating

          -  Patient is unavailable for follow-up

          -  Any angiographic or clinical evidence that the physician feels would place the patient
             at increased risk with the use of the experimental device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Chiu Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Presbyterian Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Memorial Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hosptial</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Care Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine at Barnes-Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Health Systems</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SJH Cardiology Associates</name>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <zip>13088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital - Cornell Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Heart Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hahnemann Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Heart &amp; Vascular Group</name>
      <address>
        <city>Wormleysburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wong SC, Bachinsky W, Cambier P, Stoler R, Aji J, Rogers JH, Hermiller J, Nair R, Hutman H, Wang H; ECLIPSE Trial Investigators. A randomized comparison of a novel bioabsorbable vascular closure device versus manual compression in the achievement of hemostasis after percutaneous femoral procedures: the ECLIPSE (Ensure's Vascular Closure Device Speeds Hemostasis Trial). JACC Cardiovasc Interv. 2009 Aug;2(8):785-93. doi: 10.1016/j.jcin.2009.06.006.</citation>
    <PMID>19695549</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2006</study_first_submitted>
  <study_first_submitted_qc>June 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2006</study_first_posted>
  <results_first_submitted>February 27, 2012</results_first_submitted>
  <results_first_submitted_qc>February 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 19, 2012</results_first_posted>
  <last_update_submitted>May 25, 2012</last_update_submitted>
  <last_update_submitted_qc>May 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2012</last_update_posted>
  <responsible_party>
    <name_title>Chao-Chin Chen, Vice President</name_title>
    <organization>Ensure Medical</organization>
  </responsible_party>
  <keyword>Closure Device</keyword>
  <keyword>Angiography</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Hemostasis</keyword>
  <keyword>Heart Catheterization</keyword>
  <keyword>Peripheral Angiography</keyword>
  <keyword>Femoral Closure</keyword>
  <keyword>Vascular Closure</keyword>
  <keyword>Coronary Angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Roll-In</title>
          <description>Roll-In patients were device training patients</description>
        </group>
        <group group_id="P2">
          <title>Vascular Closure Device</title>
          <description>Ensure Medical Vascular Closure Device (VCD) have been developed to avoid manual compression, shorten bed rest, and allow earlier ambulation.</description>
        </group>
        <group group_id="P3">
          <title>Manual Compression</title>
          <description>Traditionally Hemostasis at the femoral artery access site after diagnostic or interventional procedures is typically achieved using either manual compression (with or without the use of adjunctive mechanical compression devices)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="267"/>
                <participants group_id="P3" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="259"/>
                <participants group_id="P3" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Roll-In</title>
          <description>Roll-In patients were device training patients</description>
        </group>
        <group group_id="B2">
          <title>Vascular Closure Device</title>
          <description>Ensure Medical Vascular Closure Device (VCD) have been developed to avoid manual compression, shorten bed rest, and allow earlier ambulation.</description>
        </group>
        <group group_id="B3">
          <title>Manual Compression</title>
          <description>Traditionally Hemostasis at the femoral artery access site after diagnostic or interventional procedures is typically achieved using either manual compression (with or without the use of adjunctive mechanical compression devices)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="267"/>
            <count group_id="B3" value="134"/>
            <count group_id="B4" value="488"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" spread="11.61"/>
                    <measurement group_id="B2" value="63.3" spread="11.13"/>
                    <measurement group_id="B3" value="61.4" spread="10.47"/>
                    <measurement group_id="B4" value="62.8" spread="11.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="126"/>
                    <measurement group_id="B4" value="470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="267"/>
                    <measurement group_id="B3" value="134"/>
                    <measurement group_id="B4" value="488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Hemostasis (TTH)</title>
        <description>Time to hemostasis is defined as time (in minutes) from when the introducer sheath was removed to the time that hemostasis was first observed during post-procedure follow up. Hemostasis is defined as no or minimal subcutaneous oozing and the absence of expanding or developing hematoma. Time to hemostasis is one of the two co-primary endpoints.</description>
        <time_frame>From when the introducer sheath was removed to the time hemostasis was first observed</time_frame>
        <population>Intent to treat population (ITT) with non-missing time to hemostasis data. ITT population consists of all randomized (VCD and MC) patients where a femoral artery closure procedure is attempted post-randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Roll-In</title>
            <description>patients were device training patients</description>
          </group>
          <group group_id="O2">
            <title>Vascular Closure Device</title>
            <description>Ensure Medical Vascular Closure Device (VCD) have been developed to avoid manual compression, shorten bed rest, and allow earlier ambulation.</description>
          </group>
          <group group_id="O3">
            <title>Manual Compression</title>
            <description>Traditionally Hemostasis at the femoral artery access site after diagnostic or interventional procedures is typically achieved using either manual compression (with or without the use of adjunctive mechanical compression devices)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hemostasis (TTH)</title>
          <description>Time to hemostasis is defined as time (in minutes) from when the introducer sheath was removed to the time that hemostasis was first observed during post-procedure follow up. Hemostasis is defined as no or minimal subcutaneous oozing and the absence of expanding or developing hematoma. Time to hemostasis is one of the two co-primary endpoints.</description>
          <population>Intent to treat population (ITT) with non-missing time to hemostasis data. ITT population consists of all randomized (VCD and MC) patients where a femoral artery closure procedure is attempted post-randomization.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.68" spread="19.37"/>
                    <measurement group_id="O2" value="4.38" spread="11.59"/>
                    <measurement group_id="O3" value="20.05" spread="22.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: The mean time to hemostasis for the manual compression (MC) arm is less or equal to that for the vascular closure device (VCD) arm.
The trial is powered to detect a 5 minute reduction in mean time to hemostasis and a 2 hour reduction in mean time to ambulation for VCD vs. MC with over 90% power and a 5% two-sided (2.5% one-sided) Type I error</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity is addressed for the two co-primary effectiveness endpoints via a closed testing procedure where the time to hemostasis will be assessed first and then time to ambulation only if significance is first achieved for time to hemostasis.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-15.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.04</ci_lower_limit>
            <ci_upper_limit>-12.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Ambulation (TTA)</title>
        <description>Time to ambulation is defined as the time from when the introducer sheath was removed to the time that ambulation was achieved. Ambulation is defined as patient standing and walking at least 20 feet without re-bleeding or significant oozing requiring manual compression. Time to ambulation is one of the two co-primary endpoints.</description>
        <time_frame>From when the introducer sheath was removed to 30 days post-procedure</time_frame>
        <population>Intent to Treat (ITT)Population with non-missing time to ambulation data.</population>
        <group_list>
          <group group_id="O1">
            <title>Roll-In</title>
            <description>Roll-In patients were device training patients</description>
          </group>
          <group group_id="O2">
            <title>Vascular Closure Device</title>
            <description>Ensure Medical Vascular Closure Device (VCD) have been developed to avoid manual compression, shorten bed rest, and allow earlier ambulation.</description>
          </group>
          <group group_id="O3">
            <title>Manual Compression</title>
            <description>Traditionally Hemostasis at the femoral artery access site after diagnostic or interventional procedures is typically achieved using either manual compression (with or without the use of adjunctive mechanical compression devices)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Ambulation (TTA)</title>
          <description>Time to ambulation is defined as the time from when the introducer sheath was removed to the time that ambulation was achieved. Ambulation is defined as patient standing and walking at least 20 feet without re-bleeding or significant oozing requiring manual compression. Time to ambulation is one of the two co-primary endpoints.</description>
          <population>Intent to Treat (ITT)Population with non-missing time to ambulation data.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="264"/>
                <count group_id="O3" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="2.59"/>
                    <measurement group_id="O2" value="2.54" spread="5.02"/>
                    <measurement group_id="O3" value="6.24" spread="13.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis:The mean time to ambulation for the manual compression (MC) arm is less or equal to that for the vascular closure device (VCD) arm.
The trial is powered to detect a 5 minute reduction in mean time to hemostasis and a 2 hour reduction in mean time to ambulation for VCD vs. MC with over 90% power and a 5% two-sided (2.5% one-sided) Type I error</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0028</p_value>
            <p_value_desc>Multiplicity is addressed for the two co-primary effectiveness endpoints via a closed testing procedure where the time to hemostasis will be assessed first and then time to ambulation only if significance is first achieved for time to hemostasis.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-3.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.53</ci_lower_limit>
            <ci_upper_limit>-1.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Who Experience Any Vascular Closure Related Major Adverse Events During the 30 Days Post-procedure</title>
        <description>Vascular closure related major adverse events consist of any of the events below: Vascular repair or the need for repair; access site-related bleeding requiring transfusion; access site-related infection requiring intravenous/intramuscular antibiotics and/or extended hospitalization; any new ipsilateral lower extremity ischemia documented by symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram; surgery for access site-related nerve injury; and Permanent (&gt; 30 days) access site-related nerve injury.</description>
        <time_frame>From post-procedure to 30 days follow up</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Roll-In</title>
            <description>Roll-In patients were device training patients</description>
          </group>
          <group group_id="O2">
            <title>Vascular Closure Device</title>
            <description>Ensure Medical Vascular Closure Device (VCD) have been developed to avoid manual compression, shorten bed rest, and allow earlier ambulation.</description>
          </group>
          <group group_id="O3">
            <title>Manual Compression</title>
            <description>Traditionally Hemostasis at the femoral artery access site after diagnostic or interventional procedures is typically achieved using either manual compression (with or without the use of adjunctive mechanical compression devices)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Experience Any Vascular Closure Related Major Adverse Events During the 30 Days Post-procedure</title>
          <description>Vascular closure related major adverse events consist of any of the events below: Vascular repair or the need for repair; access site-related bleeding requiring transfusion; access site-related infection requiring intravenous/intramuscular antibiotics and/or extended hospitalization; any new ipsilateral lower extremity ischemia documented by symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram; surgery for access site-related nerve injury; and Permanent (&gt; 30 days) access site-related nerve injury.</description>
          <population>Intent to treat population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Based on pre-planned hypotheses, a minimum sample size of 390 randomized patients (260 VCD patients and 130 MC patients) would demonstrate non-inferiority for the primary safety endpoint and superiority for both co-primary effectiveness endpoints in comparing VCD vs. MC.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is adequate to rule out a 4% or larger disadvantage for VCD vs. MC (null hypothesis: 2.5% MC vs. 6.5% VCD) in the incidence of major complications for VCD vs. MC using a 95% upper confidence bound for the VCD  MC difference with 80% power and a 5% one-sided Type I error</non_inferiority_desc>
            <p_value>0.0006</p_value>
            <p_value_desc>P-value was calculated using unconditional exact test of non-inferiority for difference of two binomial proportions (VCD vs. MC) with a margin of 4%.</p_value_desc>
            <method>unconditional exact test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Eligibility for Hospital Discharge</title>
        <description>Time to Eligibility for Hospital Discharge is measured from the time of sheath removal to the time when the patient is eligible for discharge according to the judgment of the patients physician.</description>
        <time_frame>From introducer sheath removal to hospital discharge, up to 284 hours</time_frame>
        <population>Intent to treat population with non-missing time data</population>
        <group_list>
          <group group_id="O1">
            <title>Roll-In</title>
            <description>Roll-In patients were device training patients</description>
          </group>
          <group group_id="O2">
            <title>Vascular Closure Device</title>
            <description>Ensure Medical Vascular Closure Device (VCD) have been developed to avoid manual compression, shorten bed rest, and allow earlier ambulation.</description>
          </group>
          <group group_id="O3">
            <title>Manual Compression</title>
            <description>Traditionally Hemostasis at the femoral artery access site after diagnostic or interventional procedures is typically achieved using either manual compression (with or without the use of adjunctive mechanical compression devices)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Eligibility for Hospital Discharge</title>
          <description>Time to Eligibility for Hospital Discharge is measured from the time of sheath removal to the time when the patient is eligible for discharge according to the judgment of the patients physician.</description>
          <population>Intent to treat population with non-missing time data</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="257"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.72" spread="14.15"/>
                    <measurement group_id="O2" value="12.57" spread="13.91"/>
                    <measurement group_id="O3" value="16.25" spread="27.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: The mean time to eligibility for hospital discharge for the manual compression (MC) arm is equal to that for the vascular closure device (VCD) arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1540</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.84</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Hospital Discharge</title>
        <description>Time to hospital discharge is defined as from the time of sheath removal to the time of hospital discharge</description>
        <time_frame>From introducer sheath removal to patient discharge</time_frame>
        <population>Intent to Treat population with non-missing time data</population>
        <group_list>
          <group group_id="O1">
            <title>Roll-In</title>
            <description>Roll-In patients were device training patients</description>
          </group>
          <group group_id="O2">
            <title>Vascular Closure Device</title>
            <description>Ensure Medical Vascular Closure Device (VCD) have been developed to avoid manual compression, shorten bed rest, and allow earlier ambulation.</description>
          </group>
          <group group_id="O3">
            <title>Manual Compression</title>
            <description>Traditionally Hemostasis at the femoral artery access site after diagnostic or interventional procedures is typically achieved using either manual compression (with or without the use of adjunctive mechanical compression devices)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hospital Discharge</title>
          <description>Time to hospital discharge is defined as from the time of sheath removal to the time of hospital discharge</description>
          <population>Intent to Treat population with non-missing time data</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="264"/>
                <count group_id="O3" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.64" spread="18.54"/>
                    <measurement group_id="O2" value="16.77" spread="19.79"/>
                    <measurement group_id="O3" value="19.35" spread="29.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: The mean time to hospital discharge for the manual compression (MC) arm is equal to that for the vascular closure device (VCD) arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3612</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.46</ci_lower_limit>
            <ci_upper_limit>2.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Device Deployment, up to 5 Minutes</title>
        <description>Time to device deployment is defined as from the time device inserted to the time sheath removed</description>
        <time_frame>From device inserted to introducer sheath removal</time_frame>
        <population>Intent to Treat population with non-missing time data, excluding MC patients. Patients in the MC arm didn't deploy the device.</population>
        <group_list>
          <group group_id="O1">
            <title>Roll-In</title>
            <description>Roll-In patients were device training patients</description>
          </group>
          <group group_id="O2">
            <title>Vascular Closure Device</title>
            <description>Ensure Medical Vascular Closure Device (VCD) have been developed to avoid manual compression, shorten bed rest, and allow earlier ambulation.</description>
          </group>
          <group group_id="O3">
            <title>Manual Compression</title>
            <description>Traditionally Hemostasis at the femoral artery access site after diagnostic or interventional procedures is typically achieved using either manual compression (with or without the use of adjunctive mechanical compression devices)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Device Deployment, up to 5 Minutes</title>
          <description>Time to device deployment is defined as from the time device inserted to the time sheath removed</description>
          <population>Intent to Treat population with non-missing time data, excluding MC patients. Patients in the MC arm didn't deploy the device.</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="260"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="1.13"/>
                    <measurement group_id="O2" value="1.01" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Achieved Device Success Within Five Minutes Post-procedure</title>
        <description>Device Success is defined as the successful deployment of the plug, initial hemostasis time less or equal to 5 minutes, and removal of the intact delivery system.</description>
        <time_frame>Within 5 minutes post-procedure</time_frame>
        <population>Intent to treat population (ITT) excluding the Manual Compression (MC) patients since MC Patients didn't deploy the device.</population>
        <group_list>
          <group group_id="O1">
            <title>Roll-In</title>
            <description>Roll-In patients were device training patients</description>
          </group>
          <group group_id="O2">
            <title>Vascular Closure Device</title>
            <description>Ensure Medical Vascular Closure Device (VCD) have been developed to avoid manual compression, shorten bed rest, and allow earlier ambulation.</description>
          </group>
          <group group_id="O3">
            <title>Manual Compression (Not Applicable for Device Success)</title>
            <description>Traditionally Hemostasis at the femoral artery access site after diagnostic or interventional procedures is typically achieved using either manual compression (with or without the use of adjunctive mechanical compression devices)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Achieved Device Success Within Five Minutes Post-procedure</title>
          <description>Device Success is defined as the successful deployment of the plug, initial hemostasis time less or equal to 5 minutes, and removal of the intact delivery system.</description>
          <population>Intent to treat population (ITT) excluding the Manual Compression (MC) patients since MC Patients didn't deploy the device.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4"/>
                    <measurement group_id="O2" value="89.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients Who Achieved Procedure Success During 30 Days Post-procedure</title>
        <description>Procedure success is defined as initial hemostasis achieved by the assigned method Vascular Closure Device (VCD) or Manual compression (MC) with none of the primary safety endpoints closure related major adverse events (MAE). Procedural success is assessed on day of catheterization procedure and at 30 days post-procedure.</description>
        <time_frame>From catheterization procedure to 30 day post-procedure follow up</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Roll-In</title>
            <description>Roll-In patients were device training patients</description>
          </group>
          <group group_id="O2">
            <title>Vascular Closure Device</title>
            <description>Ensure Medical Vascular Closure Device (VCD) have been developed to avoid manual compression, shorten bed rest, and allow earlier ambulation.</description>
          </group>
          <group group_id="O3">
            <title>Manual Compression</title>
            <description>Traditionally Hemostasis at the femoral artery access site after diagnostic or interventional procedures is typically achieved using either manual compression (with or without the use of adjunctive mechanical compression devices)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Who Achieved Procedure Success During 30 Days Post-procedure</title>
          <description>Procedure success is defined as initial hemostasis achieved by the assigned method Vascular Closure Device (VCD) or Manual compression (MC) with none of the primary safety endpoints closure related major adverse events (MAE). Procedural success is assessed on day of catheterization procedure and at 30 days post-procedure.</description>
          <population>Intent to Treat Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4"/>
                    <measurement group_id="O2" value="91.8"/>
                    <measurement group_id="O3" value="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: The percentages of patients achieving procedure success between the vascular closure device and manual compression arms are equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Proportion difference</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Experienced Any Other Vascular Closure Related Adverse Events</title>
        <description>Other known vascular closure related adverse events include: Rebleeding Following Initial Hemostasis; Access Site Hematoma &gt;= 6cm; Access Site-Related Bleeding Requiring &gt; 30 min for Hemostasis; Transient Access Site-Related Nerve Injury; Retroperitonea Bleeding; Decrease in Pedal Pulse</description>
        <time_frame>From end of vessel closure procedure to 30 days post-procedure</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Roll-In</title>
            <description>Roll-In patients were device training patients</description>
          </group>
          <group group_id="O2">
            <title>Vascular Closure Device</title>
            <description>Ensure Medical Vascular Closure Device (VCD) have been developed to avoid manual compression, shorten bed rest, and allow earlier ambulation.</description>
          </group>
          <group group_id="O3">
            <title>Manual Compression</title>
            <description>Traditionally Hemostasis at the femoral artery access site after diagnostic or interventional procedures is typically achieved using either manual compression (with or without the use of adjunctive mechanical compression devices)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Experienced Any Other Vascular Closure Related Adverse Events</title>
          <description>Other known vascular closure related adverse events include: Rebleeding Following Initial Hemostasis; Access Site Hematoma &gt;= 6cm; Access Site-Related Bleeding Requiring &gt; 30 min for Hemostasis; Transient Access Site-Related Nerve Injury; Retroperitonea Bleeding; Decrease in Pedal Pulse</description>
          <population>Intent to treat population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="8.99"/>
                    <measurement group_id="O3" value="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Roll-In</title>
          <description>Roll-In patients were device training patients</description>
        </group>
        <group group_id="E2">
          <title>Vascular Closure Device</title>
          <description>Ensure Medical Vascular Closure Device (VCD) have been developed to avoid manual compression, shorten bed rest, and allow earlier ambulation.</description>
        </group>
        <group group_id="E3">
          <title>Manual Compression</title>
          <description>Traditionally Hemostasis at the femoral artery access site after diagnostic or interventional procedures is typically achieved using either manual compression (with or without the use of adjunctive mechanical compression devices)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Rebleeding Following Initial Hemostasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="267"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Access Site Hematoma &gt;= 6cm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="267"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Access Site-Related Bleeding Requiring &gt; 30 min for Hemostasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Eochymosis &gt;= 6cm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Decrease in Pedal Pulse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Access Site-Related Nerve Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hans-Peter Stoll, M.D.</name_or_title>
      <organization>Cordis Corporation, a Johnson&amp;Johnson company</organization>
      <phone>908-541-4770</phone>
      <email>hpstoll@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

